Highlights BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
2.35 ^USD	-6.37%		-6.75%	-20.34%

Apr. 22	BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	MT
Apr. 22	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	Apr. 22	MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	Apr. 22	CI
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	Apr. 10	CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	Mar. 25	MT
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	Mar. 15	MT
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 12	CI
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	Feb. 12	MT
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation	Feb. 12	DJ
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer	Feb. 12	CI
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Feb. 09	MT
BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda®	Feb. 06	CI
BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine	Feb. 05	CI
BioXcel Therapeutics Aligning With FDA Recommendation on Phase 3 Trial, Agrees to Amended Financing Terms	Nov. 14	MT
BioXcel Therapeutics Shares Sink After Weak 3Q	Nov. 14	DJ
BioXcel Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
BioXcel Therapeutics, Inc. Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer of Adenocarcinoma Phenotype	Nov. 08	CI
BioXcel Therapeutics Shares Rise After Treatment for Schizophrenia-Associated Agitation Gets Medicare Code	23-10-30	MT
Bioxcel Therapeutics, Inc. Receives Permanent J-Code for Igalmi (Dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services	23-10-30	CI
Top Premarket Gainers	23-10-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Highlights

Filters